Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled

Executive Summary

Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate

You may also be interested in...



Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?

Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics

Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?

Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics

FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key

The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel